Ferring Pharmaceuticals will present new research across four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and online. The abstracts include two oral and two poster presentations, reflecting Ferring’s commitment to advancing fertility care and addressing diverse family-building needs.
Sasmira Lalwani, Senior Medical Director of Reproductive Medicine at Ferring, emphasized that the data shared at the congress will provide valuable insights for healthcare professionals and fertility clinic staff. “Our presentations highlight our efforts to advance science, support diverse family-building needs, and offer educational resources for fertility specialists,” said Lalwani.
The four abstracts cover significant topics in reproductive medicine:
- “Advancing Fertility Equity: Uplifting Black Women’s Voices to Design Culturally Responsive Support Solutions” – Poster #24, presented on October 21 from 10:45-11:00 a.m. MDT.
- “Patterns of Utilization of Advanced Practice Providers in Reproductive Endocrinology: A 2023 National Survey” – Oral Presentation #184, on October 22 from 11:45-11:56 a.m. MDT.
- “Impact of Gonadotropin Selection on Risk of Ovarian Hyperstimulation Syndrome (OHSS) in Predicted High Responders Undergoing Ovarian Stimulation: A Megaset-HR Trial Analysis” – Oral Presentation #154, on October 22 from 10:56-11:07 a.m. MDT.
- “Assessing the Impact of an eLearning Platform for Educating Fertility Professionals” – Poster #652, on October 23 from 11:30-11:45 a.m. MDT.
In addition to these presentations, Ferring will host a panel discussion titled “Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation” on October 21 at 10:05 a.m. MDT. The session will cover legislative and policy initiatives aimed at expanding access to infertility treatments.
Panelists include Tim Clark, Ferring’s Director of Government Affairs; Dr. Serena H. Chen, a reproductive endocrinologist and Director of Advocacy at CCRM NJ; Dr. Michael A. Thomas, Chair of the Department of Obstetrics and Gynecology at the University of Cincinnati; and Sean B. Tipton, Chief Advocacy & Policy Officer at ASRM.
David Powley, Vice President of Reproductive Medicine and Operations at Ferring, reiterated the company’s long-standing dedication to helping people achieve parenthood through innovations in reproductive medicine and expanding access to in vitro fertilization.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
